Mounjaro Vs Ozempic For Weight Loss: Which Is Better? - Guide | Cured Pharmacy

Mounjaro Vs Ozempic For Weight Loss: Which Is Better?

WEIGHT LOSS · 22 MIN READ
Written by Cured Pharmacy
Published on 14 August 2026
★★★★★ Judge.me Reviews
Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

Featured Product

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

From£145.00£124.99 UK-based prescribers · Discreet delivery · Free private prescription
Start Assessment → ✓ Lowest price guarantee
DISCOUNT CODE: FIRST20

£20 off for new patients

Tarun Kumar, Prescribing Pharmacist at Cured Pharmacy

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 14 August 2026

If you have been researching weight loss injections, you have almost certainly found yourself deep in the weeds of one particular debate that refuses to go away: which medication actually works better, Mounjaro or Ozempic? Both have earned genuine praise from patients and clinicians alike, both are backed by serious clinical data, and both represent a genuine step change in how we approach obesity treatment in the UK. But they are not the same drug, they do not work in exactly the same way, and for many people, the differences matter enormously. Whether you are newly eligible for treatment, switching from one medication to another, or simply trying to make a confident, informed choice before you speak to a prescriber, this guide cuts through the noise and gives you real, clinically grounded answers.

Summary

Both Mounjaro and Ozempic are injectable medications approved for use in the UK that have transformed weight management for thousands of people. Mounjaro (tirzepatide) works on two hormone receptors simultaneously, while Ozempic (semaglutide) targets one, and that distinction plays out in the clinical trial data in ways that genuinely matter to patients choosing between them.

  • Mounjaro (tirzepatide) produces average weight loss of up to 22.5% of body weight in clinical trials, compared to around 15% for semaglutide at the highest doses.
  • Ozempic is primarily licensed for type 2 diabetes in the UK; Wegovy (also semaglutide) is the weight-loss-specific version at a higher dose.
  • Both medications carry similar side effect profiles, predominantly gastrointestinal, but Mounjaro's dual action may offer additional metabolic benefits.
  • Cost, availability, and prescriber access vary significantly between the two, and Cured Pharmacy offers a streamlined, affordable route to Mounjaro with UK-based prescribers.
  • Using discount code FIRST20 at Cured Pharmacy saves new patients £20 off their first Mounjaro order.

Table of Contents

  1. How Mounjaro and Ozempic Actually Work
  2. Weight Loss Results: What the Clinical Evidence Really Shows
  3. Side Effects and Safety: An Honest Comparison
  4. Who Is Eligible for Each Medication in the UK?
  5. Cost, Availability, and Getting Started in the UK
  6. Mounjaro vs Ozempic for Weight Loss: Which Is Better for You?
  7. Side-by-Side Comparison Table
  8. Key Takeaways
  9. When to Seek Professional Advice
  10. Scientific References
  11. FAQs

How Mounjaro and Ozempic Actually Work

Weight Loss Timeline Estimator

Enter your details to estimate your potential weight loss journey with GLP-1 medications. This is a general guide only and not a substitute for clinical advice.

Understanding the mechanism behind each drug helps explain why the results differ so significantly. Ozempic contains semaglutide, a GLP-1 receptor agonist. GLP-1, or glucagon-like peptide-1, is a hormone your gut naturally releases after eating. It signals to the brain that you are full, slows gastric emptying, and stimulates insulin release. Semaglutide mimics this hormone exceptionally well, which is why it became a breakthrough treatment for both type 2 diabetes and, at higher doses as Wegovy, for weight management. You can explore weight loss treatment options at Cured Pharmacy to see both medications side by side.

Mounjaro, on the other hand, contains tirzepatide and operates on two receptors simultaneously: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual agonism is what earns Mounjaro its reputation as a step ahead. GIP works synergistically with GLP-1, enhancing insulin sensitivity, reducing appetite through a slightly different pathway, and influencing how fat tissue stores and burns energy. When both systems are activated together, the appetite-suppressing and metabolic effects are amplified beyond what either hormone achieves alone. This dual mechanism is, in plain terms, why the Mounjaro vs Ozempic for weight loss debate so consistently leans toward Mounjaro when pure weight reduction is the goal.

  • Ozempic/semaglutide: single GLP-1 receptor agonist
  • Mounjaro/tirzepatide: dual GLP-1 and GIP receptor agonist
  • Dual agonism creates synergistic metabolic and appetite-suppressing effects
  • Both drugs are administered as once-weekly subcutaneous injections
  • Both are incremented gradually from a starting dose to reduce side effects

Weight Loss Results: What the Clinical Evidence Really Shows

The clinical evidence here is genuinely striking, and it is worth spending some time with the actual numbers rather than vague claims. The SURMOUNT-1 trial, published in the New England Journal of Medicine, demonstrated that tirzepatide at its highest dose of 15 mg produced a mean weight reduction of 22.5% of body weight over 72 weeks in adults with obesity but without type 2 diabetes. To put that in real-world terms: a person weighing 120 kg could expect to lose approximately 27 kg on average. That is transformative, not incremental. The Mounjaro vs Ozempic for Weight Loss: Which Is Better? question becomes considerably clearer when you compare this to the STEP-1 trial for semaglutide 2.4 mg (Wegovy), which showed a mean weight loss of approximately 14.9% over 68 weeks.

What is particularly important to understand is that these are averages. Some participants in the SURMOUNT trials lost considerably more, while others lost less. The responder rates are also informative: in SURMOUNT-1, over 90% of participants on the highest tirzepatide dose achieved at least 5% weight loss, around 50% achieved at least 20% weight loss, and around 35% achieved at least 25% weight loss. These are not numbers we see routinely with any other obesity pharmacotherapy. For patients who have previously plateaued on semaglutide, switching to tirzepatide has shown meaningful additional benefit in early real-world data emerging in 2026.

  • SURMOUNT-1 (tirzepatide 15 mg): mean 22.5% body weight loss over 72 weeks
  • STEP-1 (semaglutide 2.4 mg): mean 14.9% body weight loss over 68 weeks
  • Tirzepatide responder rates substantially higher across all weight loss thresholds
  • Head-to-head comparison data strongly favours tirzepatide for weight reduction
  • Both medications outperform lifestyle intervention alone by a significant margin

A landmark head-to-head trial, SURMOUNT-5, published in 2025, directly compared tirzepatide with semaglutide 2.4 mg in adults with obesity. Participants on tirzepatide lost approximately 47% more weight than those on semaglutide. This is the clearest direct evidence yet and settles what was previously an indirect comparison based on separate trials. If you are weighing up the Wegovy semaglutide weight loss injection against Mounjaro, these numbers deserve serious consideration.

Side Effects and Safety: An Honest Comparison

Neither medication is without side effects, and it would be misleading to suggest otherwise. The most commonly reported adverse effects for both tirzepatide and semaglutide are gastrointestinal in nature: nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These effects are almost always more pronounced during the dose titration phase, the period of several weeks where the dose is gradually increased to the maintenance level, and they typically ease significantly once the body adjusts. Both medications are started at low doses precisely to give the digestive system time to adapt.

In the SURMOUNT and STEP trials, the rates of nausea and gastrointestinal discontinuation were broadly comparable between the two drugs, although some analyses suggest slightly higher rates of nausea with tirzepatide at the highest doses. For most patients, these effects are manageable, particularly with practical strategies such as eating smaller meals, avoiding high-fat foods, and staying well hydrated. Both medications carry a rare but real risk of pancreatitis and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2. A prescriber will screen for these conditions before initiating treatment.

  • Most common: nausea, vomiting, diarrhoea, constipation (both drugs equally)
  • Side effects peak during dose escalation and typically reduce over time
  • Both carry black-box warnings regarding thyroid C-cell tumours (animal data)
  • Pancreatitis risk is rare but real for both medications
  • Gallbladder issues (gallstones, cholecystitis) are more common with significant rapid weight loss on either drug

One area where there is emerging differentiation is the cardiovascular evidence base. The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events in people with obesity and established cardiovascular disease. Similar cardiovascular outcome data for tirzepatide are expected from the SURMOUNT-MMO trial, with results eagerly anticipated by the clinical community. As of 2026, semaglutide carries stronger cardiovascular evidence, which is a relevant factor for patients with pre-existing heart disease making treatment decisions.

Who Is Eligible for Each Medication in the UK?

Understanding eligibility is crucial, and the rules in the UK are specific. Ozempic (semaglutide 0.5 mg, 1 mg, and 2 mg) is licensed by the MHRA for the treatment of type 2 diabetes and is not, strictly speaking, licensed for weight loss at these doses. Wegovy (semaglutide 2.4 mg) is the formulation specifically licensed for chronic weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity. NICE guidance NG246, published in 2023, recommends Wegovy within a specialist weight management service, meaning NHS access involves referral to a specialist service, which has created significant waiting times in practice.

Mounjaro (tirzepatide) received MHRA approval for weight management in adults with obesity in the UK and NICE approved it for NHS use in 2024 under specific eligibility criteria. NHS access is similarly restricted to specialist weight management services and carries BMI-based criteria. However, Mounjaro is widely available through private prescription in the UK, and this is where providers like Cured Pharmacy play a genuinely important role. Through an online consultation with a UK-based prescriber, eligible patients can access Mounjaro quickly, without NHS waiting lists, at a price that is significantly more competitive than many private clinics. New patients can also use discount code FIRST20 to save £20 on their first order.

  • Wegovy: licensed for weight management, BMI 30+ or 27+ with comorbidities
  • Ozempic: licensed for type 2 diabetes only, off-label use for weight loss is clinically common but technically outside its licensed indication
  • Mounjaro: MHRA-approved for weight management, NICE-recommended for NHS use in eligible patients
  • NHS access for both involves specialist referral and can involve significant wait times
  • Private prescriptions via providers like Cured Pharmacy offer faster, more accessible routes to treatment

Cost, Availability, and Getting Started in the UK

Cost is, honestly, one of the most significant practical barriers to treatment for many people, and it is worth being frank about it. On the NHS, eligible patients can access Wegovy and Mounjaro through specialist weight management services without prescription charges (though in England, NHS prescription charges apply unless exempt). However, the reality is that most people cannot access these services quickly. Private treatment costs vary widely.

Many private clinics and online prescribers charge considerably more than necessary, particularly when you factor in consultation fees, follow-up charges, and inflated medication costs. Cured Pharmacy takes a different approach. Their Mounjaro offering starts from £124.99 after discount, with UK-based prescribers, a free private prescription, and discreet delivery to your door. Compared with clinics charging £200 or more per pen before consultation fees, this represents genuine value. The platform's online medical assessment is thorough, properly regulated, and conducted by qualified UK prescribers, meaning safety is not compromised for convenience.

Ozempic availability in the UK has been intermittent due to supply shortages that began in 2022 and have persisted through 2024 and into 2025. Many patients prescribed Ozempic for diabetes found themselves unable to obtain it as demand from weight loss users outstripped supply. Mounjaro, while also in high demand, has had more consistent supply availability, making it a more reliable option for those seeking uninterrupted treatment. Cured Pharmacy stocks Mounjaro and clearly communicates availability, which reduces the anxiety of chasing medication across multiple pharmacies.

  • NHS access: limited by specialist referral and waiting times
  • Cured Pharmacy: from £124.99 for Mounjaro, free private prescription, UK prescribers
  • New patients save £20 with code FIRST20 at Cured Pharmacy
  • Ozempic supply has been intermittently disrupted in the UK; Mounjaro supply has been more consistent
  • Online assessments at Cured Pharmacy are quick, regulated, and conducted by qualified UK clinicians

It is also worth noting that Cured Pharmacy provides ongoing support, not just a one-off prescription. Weight loss medication works best when combined with dietary and lifestyle guidance, and knowing your prescriber is accessible matters. You can start your journey by visiting the weight loss collection at Cured Pharmacy to compare available treatment options and begin your online assessment today.

Mounjaro vs Ozempic for Weight Loss: Which Is Better for You?

This is the question that matters most, and the honest answer is: it depends on your individual health profile, your goals, and your access to treatment. But if pure weight loss is the primary goal, the clinical evidence is unambiguous. Tirzepatide (Mounjaro) produces substantially greater weight reduction than semaglutide at its highest doses, and the head-to-head SURMOUNT-5 data makes this argument conclusively. For patients without type 2 diabetes who simply want the most effective tool available for significant weight reduction, Mounjaro is, by the data, the stronger option.

That said, semaglutide (whether as Ozempic for diabetes management or Wegovy for weight loss) is an outstanding medication that has helped hundreds of thousands of people in the UK. If you have established cardiovascular disease, the cardiovascular outcomes data for semaglutide is stronger at this point in time. If you have previously tried Mounjaro and not tolerated it, or if Mounjaro is contraindicated for you, Wegovy is a highly effective alternative. Discussing your full medical history with a prescriber is non-negotiable before starting either medication. You might also find it helpful to read about all available weight loss injection options to understand the full picture before your consultation.

From a real-world perspective, I have spoken to patients who found that Ozempic gave them a manageable reduction in appetite without the more intense nausea some report with higher-dose tirzepatide. Others found that after months on Wegovy, switching to Mounjaro unlocked a plateau they had been stuck at for several weeks. Weight loss medication is not one-size-fits-all, and a good prescriber will help you navigate that nuance rather than simply dispensing whatever is most popular.

  • For maximum weight loss: Mounjaro (tirzepatide) is the evidence-based first choice
  • For cardiovascular risk reduction in obesity: semaglutide has stronger outcomes data currently
  • For diabetes management specifically: Ozempic remains the primary option
  • Individual tolerability varies: some patients do better on one drug than the other
  • Both require professional assessment, dose titration, and monitoring

Side-by-Side Comparison Table

Feature Mounjaro (Tirzepatide) Ozempic/Wegovy (Semaglutide)
Drug class Dual GLP-1/GIP receptor agonist GLP-1 receptor agonist
UK licence for weight loss Yes (Mounjaro, MHRA approved) Yes (Wegovy); Ozempic is for type 2 diabetes
Average weight loss (max dose) Up to 22.5% body weight Up to 14.9–15% body weight
Dosing frequency Once weekly injection Once weekly injection
Starting dose 2.5 mg per week 0.25 mg per week (Wegovy)
Maximum dose 15 mg per week 2.4 mg per week (Wegovy)
Common side effects Nausea, vomiting, diarrhoea, constipation Nausea, vomiting, diarrhoea, constipation
Cardiovascular outcomes data Awaited (SURMOUNT-MMO trial ongoing) Positive (SELECT trial, 2023)
Contraindications MTC history, MEN2, pancreatitis history MTC history, MEN2, pancreatitis history
UK private cost (approx.) From £124.99 at Cured Pharmacy Varies; typically £150–£250+ per month privately
Supply reliability in UK (2025/2026) Generally good Intermittent shortages reported
Best suited for Maximum weight loss, metabolic improvement Weight loss, type 2 diabetes, cardiovascular risk

Key Takeaways

  • Mounjaro (tirzepatide) produces significantly greater average weight loss than Ozempic or Wegovy (semaglutide) based on both separate and head-to-head clinical trial data, making it the leading option when weight reduction is the primary goal.
  • Ozempic is technically licensed for type 2 diabetes in the UK; Wegovy (also semaglutide) is the weight-loss-licensed version, and it carries stronger cardiovascular outcomes evidence, which may be the deciding factor for some patients.
  • Both medications share similar side effect profiles, predominantly gastrointestinal, and require careful dose titration managed by a qualified prescriber.
  • Cured Pharmacy offers an accessible, affordable, and properly regulated route to Mounjaro in the UK, with UK-based prescribers, free private prescriptions, and new patient savings of £20 with code FIRST20.
  • Supply shortages have affected Ozempic availability in the UK more significantly than Mounjaro, making Mounjaro a more reliable choice for uninterrupted treatment in 2025 and 2026.

When to Seek Professional Advice

You should always speak to a qualified prescriber before starting, switching, or stopping either Mounjaro or Ozempic. There are specific situations where getting professional input promptly is especially important:

  • You have a personal or family history of thyroid cancer, pancreatitis, or Multiple Endocrine Neoplasia type 2, as both medications are contraindicated in these cases.
  • You are pregnant, planning to become pregnant, or breastfeeding, as neither medication is currently recommended during pregnancy.
  • You are taking other medications, particularly insulin or other diabetes drugs, where dose adjustments may be needed to avoid hypoglycaemia.
  • You experience persistent severe nausea, vomiting, or abdominal pain that does not resolve, as this may indicate pancreatitis or gallbladder disease requiring urgent assessment.
  • You have not seen meaningful weight loss after 12 weeks on the maximum tolerated dose, as your prescriber may recommend switching medications or reviewing your treatment plan.
  • You are experiencing mood changes or thoughts of self-harm, as emerging pharmacovigilance data prompts monitoring for these outcomes in some individuals.

Cured Pharmacy's online consultation connects you with UK-registered prescribers who can assess your eligibility, review your medical history, and provide ongoing support throughout your treatment. Visit the Cured Pharmacy weight loss page to begin your assessment and access the UK's most clinically rigorous yet patient-friendly route to Mounjaro.

Scientific References

  1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022 (SURMOUNT-1 trial) [Accessed 14 August 2026]
  2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021 (STEP-1 trial) [Accessed 14 August 2026]
  3. NICE Guideline NG246: Obesity: identification, assessment and management. NICE, 2023 [Accessed 14 August 2026]
  4. NICE Technology Appraisal TA1026: Tirzepatide for managing overweight and obesity. NICE, 2024 [Accessed 14 August 2026]
  5. NICE Technology Appraisal TA875: Semaglutide for managing overweight and obesity (Wegovy). NICE, 2023 [Accessed 14 August 2026]
  6. MHRA. Regulatory approval of Mounjaro (tirzepatide). UK Government, 2023 [Accessed 14 August 2026]
  7. Eli Lilly. Mounjaro (tirzepatide) Summary of Product Characteristics. Electronic Medicines Compendium (EMC), 2023 [Accessed 14 August 2026]
  8. Novo Nordisk. Wegovy (semaglutide 2.4 mg) Summary of Product Characteristics. Electronic Medicines Compendium (EMC), 2022 [Accessed 14 August 2026]
  9. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine, 2023 [Accessed 14 August 2026]
  10. Diabetes UK. GLP-1 Receptor Agonists. Diabetes UK, 2024 [Accessed 14 August 2026]
  11. British National Formulary. Tirzepatide drug monograph. BNF/NICE, 2024 [Accessed 14 August 2026]
  12. British National Formulary. Semaglutide drug monograph. BNF/NICE, 2024 [Accessed 14 August 2026]
  13. NHS. Semaglutide injection (Ozempic, Wegovy). NHS, 2024 [Accessed 14 August 2026]
  14. Del Prato S et al. Tirzepatide versus semaglutide: mechanisms, efficacy, and clinical implications. The Lancet Diabetes and Endocrinology, 2024 [Accessed 14 August 2026]
  15. Wadden TA et al. Tirzepatide versus Semaglutide for Obesity (SURMOUNT-5 trial). New England Journal of Medicine, 2025 [Accessed 14 August 2026]

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My AssessmentReturning Customer?Log In to Your Account

Frequently Asked Questions

How long does it take to see weight loss results with Mounjaro compared to Ozempic?

How long it takes to see weight loss results varies between the two medications, but most people notice initial changes within four to eight weeks of starting either drug. Mounjaro typically produces more rapid and more substantial weight loss overall, with the most significant changes occurring between months three and twelve as the dose is titrated upward toward the maintenance level.

Is Mounjaro safe to use for weight loss if I do not have diabetes?

Mounjaro is safe for weight loss in adults without diabetes, as it holds a specific MHRA licence for chronic weight management in the UK, separate from its diabetes indication. It is not a diabetic medication repurposed informally; it was developed and trialled specifically for obesity treatment and is prescribed daily to non-diabetic patients via UK prescribers including those at Cured Pharmacy.

Can you switch from Ozempic to Mounjaro for weight loss?

Yes, you can switch from Ozempic or Wegovy to Mounjaro for weight loss, and many patients do so when they plateau or wish to achieve greater results. Switching should always be managed by a prescriber who will advise on the appropriate Mounjaro starting dose, timing of the switch, and any monitoring requirements during the transition period to ensure safety and continuity of care.

What is the starting dose of Mounjaro for weight loss in the UK?

The starting dose of Mounjaro for weight loss in the UK is 2.5 mg once weekly by subcutaneous injection, typically maintained for four weeks before being increased. The dose is then titrated in 2.5 mg increments every four weeks as tolerated, up to a maximum of 15 mg weekly, which is the dose associated with the greatest average weight loss in clinical trials.

Back to blog